Wockhardt plans to launch its US FDA-approved antibiotic, Zaynich, in the US by early 2027, with European approval expected soon. The company also reported a net profit of ₹107 crore for the June 2026 quarter, a turnaround from the loss in the previous year. Despite these updates, Wockhardt shares closed 4.44% lower on August 10, 2026.
Wockhardt has detailed its commercial roadmap for its novel antibiotic, Zaynich, targeting a United States market entry by the first quarter of 2027. This update comes alongside the company's financial results for the first quarter of the 2027 financial year, where it reported a consolidated net profit of ₹107 crore, a significant turnaround from the net loss of ₹108 crore recorded in the same period last year.
Zaynich (WCK 5222) represents a milestone in Indian pharmaceutical history, as it is the first novel drug discovered and developed in India to receive US FDA approval, which was granted on May 30, 2026. The company’s Chairman, Habil Khorakiwala, announced that Wockhardt is actively preparing for the global rollout. This includes the recruitment of a dedicated commercial team, consisting of 35 to 40 medical professionals specializing in infectious diseases, who will drive the pre-launch scientific engagement with healthcare providers in the U.S. and India.
Beyond the U.S. market, Wockhardt is seeking regulatory clearance in Europe. The Marketing Authorization Application for the drug is currently under review by the European Medicines Agency, with a decision expected by December 2026 or January 2027. If approved, the drug would be cleared for use in treating various serious conditions, such as complicated urinary tract infections and hospital-acquired pneumonia.
Developing this antibiotic has been a long-term commitment for Wockhardt, involving an estimated investment of $800 million over the past 25 years. The company believes that Zaynich offers a therapeutic advantage over the current standard of care, meropenem, in treating severe infections.
Despite the positive developments regarding its flagship antibiotic and the return to profitability, Wockhardt’s stock performance on August 10, 2026, was muted. The share price closed at ₹1,931.20, down 4.44% for the day. This market reaction suggests that while investors are acknowledging the regulatory milestones, they may be exercising caution regarding the upcoming costs of global commercialization and the competitive nature of the anti-infectives sector. Success for the company will now depend on its ability to execute these international launches, secure pending approvals, and maintain the operational efficiency that helped drive the recent profit turnaround. Shareholders will likely monitor the progress of the European approval and the company’s ability to gain market traction in the U.S. after the launch.